Dimethyl Sulfoxide
drugOn this page
Also known as DimethylsulfoxydeDimetil sulfoxidoDMSOInfiltrinaNSC-763Rimso-50Rimso 50SQ 9453SQ-9453SyntexanMethanesulfinylmethaneMethanesulfinylmethane (DMSO)dimethylsulfoxideSID26757375SID144211274methylsulfinylmethaneD2650
Summary
Dimethyl Sulfoxide (CHEMBL504) is an approved small-molecule non-narcotic analgesic (ATC G04BX13); indicated across 14 conditions including cystitis and overactive bladder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: G04BX13 (+1 more)
- Indications: 14 conditions
- Clinical trials: 14
- Chemistry: 78.14 Da · C2H6OS
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL504 |
| Name | Dimethyl Sulfoxide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 679 |
| ChEBI | CHEBI:28262 |
| ATC | G04BX13, M02AX03 |
| Molecular formula | C2H6OS |
| Molecular weight | 78.14 |
| InChIKey | IAZDPXIOMUYVGZ-UHFFFAOYSA-N |
SMILES: CS(=O)C
IUPAC name: methylsulfinylmethane
ChEBI definition: A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.
Pharmacological roles (ChEBI): radical scavenger, non-narcotic analgesic, antidote, geroprotector.
Other ChEBI roles (chemical / environmental): polar aprotic solvent, Escherichia coli metabolite.
Also known as: Dimethyl sulfoxide, Dimethylsulfoxyde, Dimetil sulfoxido, DMSO, Infiltrina, NSC-763, Rimso-50, Rimso 50, SQ 9453, SQ-9453, Syntexan, Methanesulfinylmethane
Patent coverage: 594,511 distinct patent families (1,628,339 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,628,337 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
14 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cystitis | 4 | MONDO:0006032 | EFO:1000025 |
| overactive bladder | 3 | MONDO:0006624 | EFO:1000781 |
| hyperreflexia | 3 | MONDO:0007774 | HP:0001347 |
| interstitial cystitis | 2 | MONDO:0018301 | EFO:0008507 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| cutaneous melanoma | 1 | MONDO:0005012 | EFO:0000389 |
| osteoarthritis | 1 | MONDO:0005178 | MONDO:0005178 |
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00667095 | PHASE3 | TERMINATED | Over Active Bladder Instillation Study - Botox |
| NCT02206477 | PHASE2/PHASE3 | UNKNOWN | DMSO for Prevention of Capsular Contraction in Alloplastic Breast Reconstruction |
| NCT05560919 | PHASE2/PHASE3 | COMPLETED | Acceleration of Orthodontic Tooth Movement |
| NCT00317070 | PHASE2 | TERMINATED | Trial Comparing Intravesical Cocktail With Intravesical Dimethyl Sulfoxide (DMSO) in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC) |
| NCT03716583 | PHASE2 | COMPLETED | Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer |
| NCT00118313 | PHASE1 | COMPLETED | Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma |
| NCT01123915 | PHASE1 | TERMINATED | A Safety and Immunogenicity Study of 3 Doses of Opal Immunotherapy in HIV Infected People |
| NCT02337192 | PHASE1 | COMPLETED | Antimicrobial Photodynamic Therapy Applied in Orthodontic. Orthodontic Patients. |
| NCT03103594 | EARLY_PHASE1 | COMPLETED | Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A |
| NCT06635382 | Not specified | NOT_YET_RECRUITING | Clinical Evaluation of Dimethyl Sulfoxide Wet Bonding Technique |
| NCT07196618 | Not specified | ACTIVE_NOT_RECRUITING | Bond Strength Evaluation |
| NCT01069263 | Not specified | UNKNOWN | Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis |
| NCT01074567 | Not specified | UNKNOWN | DMSO Efficacy in IC/PBS Patients During and After Treatment |
| NCT04492306 | Not specified | COMPLETED | Clinical Evaluation of Dimethyl Sulfoxide Dentin Pre-treatment |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: cystitis, overactive bladder, hyperreflexia